IBIO · NASDAQ
iBio (IBIO) Stock Price & Fundamentals
iBio (IBIO) closed at $525.30 on Oct 9, 2026, down 0.41% from the previous close of $527.44.
Share price, past year
1Y −5.55%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $525.30 |
| Sep 30, 2026 | $511.90 |
| Aug 31, 2026 | $532.11 |
| Jul 31, 2026 | $537.71 |
| Jun 30, 2026 | $531.79 |
| May 29, 2026 | $556.49 |
| Apr 30, 2026 | $580.57 |
| Mar 31, 2026 | $592.83 |
| Feb 27, 2026 | $560.30 |
| Jan 30, 2026 | $539.99 |
| Dec 31, 2025 | $555.62 |
| Nov 28, 2025 | $620.72 |
| Oct 31, 2025 | $576.53 |
Key statistics
- Market cap
- $29.26B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.32
- Revenue (TTM)
- $300.00K
- Net income (TTM)
- −$33.04M
- Shares outstanding
- 55.7M
- Dividend yield
- —
- 52-week range
- $507.95 – $620.72
iBio's market cap is $29.26B, based on a share price of $525.30 and 55.7M shares outstanding as of Jun 30, 2026.
Financials
iBio reported revenue of $100.00K for fiscal 2026, down 75.00% from fiscal 2025.
iBio reported a net loss of $33.04M in fiscal 2026.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2026ended Jun 30, 2026 | $100.00K | −75.0% | −$33.04M | −33,044.0% | −$0.32 | −$23.80M |
| FY2025ended Jun 30, 2025 | $400.00K | +77.8% | −$18.38M | −4,594.3% | −$1.75 | −$15.32M |
| FY2024ended Jun 30, 2024 | $225.00K | — | −$24.91M | −11,069.8% | −$6.50 | −$18.76M |
| FY2023ended Jun 30, 2023 | $0.00 | −100.0% | −$65.01M | — | −$106.19 | −$36.17M |
| FY2022ended Jun 30, 2022 | $1.88M | −20.5% | −$50.30M | −2,670.0% | −$115.60 | −$44.81M |
| FY2021ended Jun 30, 2021 | $2.37M | +44.8% | −$23.21M | −978.8% | −$1,500.00 | −$34.98M |
| FY2020ended Jun 30, 2020 | $1.64M | −18.8% | −$16.44M | −1,003.6% | −$305.00 | −$14.42M |
| FY2019ended Jun 30, 2019 | $2.02M | +354.5% | −$17.59M | −871.8% | −$470.00 | −$14.90M |
| FY2018ended Jun 30, 2018 | $444.00K | +12.7% | −$16.11M | −3,627.3% | −$770.00 | −$14.41M |
| FY2017ended Jun 30, 2017 | $394.00K | — | −$14.53M | −3,688.3% | −$820.00 | −$14.49M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Dec 31, 2025 | $0.00 | −$8.99M | −$0.09 |
| Q1 FY2026ended Sep 30, 2025 | $100.00K | −$5.72M | −$0.11 |
| Q4 FY2025ended Jun 30, 2025 | $200.00K | −$5.16M | −$0.32 |
| Q3 FY2025ended Mar 31, 2025 | $0.00 | −$4.86M | −$0.49 |
| Q2 FY2025ended Dec 31, 2024 | $200.00K | −$4.36M | −$0.48 |
| Q1 FY2025ended Sep 30, 2024 | $0.00 | −$3.99M | −$0.46 |
| Q1 FY2024ended Sep 30, 2023 | $50.00K | — | — |
| Q4 FY2023ended Jun 30, 2023 | $0.00 | — | — |
Company profile
- Name
- iBio, Inc.
- Ticker
- IBIO
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 600 Madison Avenue, Suite 1601, New York, NY 10022-1737
- Incorporated in
- DE
- Fiscal year ends
- June
- SEC CIK
- 0001420720
Recent SEC filings
- Sep 14, 2026
- Aug 28, 2026
- Aug 28, 2026
- Aug 4, 2026
- Jul 17, 2026
- Jul 1, 2026
- May 12, 2026
- May 12, 2026
Frequently asked questions
What is iBio's stock price?
iBio (IBIO) closed at $525.30 on Oct 9, 2026, down 0.41% from the previous close of $527.44.
What is iBio's market cap?
iBio's market cap is $29.26B, based on a share price of $525.30 and 55.7M shares outstanding as of Jun 30, 2026.
How much revenue does iBio make?
iBio reported revenue of $100.00K for fiscal 2026, down 75.00% from fiscal 2025.
Does iBio pay a dividend?
iBio's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from iBio, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures